DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Thrombate III (Antithrombin III) - Summary

 


Nutrilib.com
A comprihensive source of nutritional information

THROMBATE III SUMMARY

Antithrombin III (Human), THROMBATE III® is a sterile, nonpyrogenic, stable, lyophilized preparation of purified human antithrombin III.

THROMBATE III is indicated for the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.

Subjects with AT-III deficiency should be informed about the risk of thrombosis in connection with pregnancy and surgery and about the inheritance of the disease.

The diagnosis of hereditary antithrombin III (AT-III) deficiency should be based on a clear family history of venous thrombosis as well as decreased plasma AT-III levels, and the exclusion of acquired deficiency.

AT-III in plasma may be measured by amidolytic assays using synthetic chromogenic substrates, by clotting assays, or by immunoassays. The latter does not detect all hereditary AT-III deficiencies.16

The AT-III level in neonates of parents with hereditary AT-III deficiency should be measured immediately after birth. (Fatal neonatal thromboembolism, such as aortic thrombi in children of women with hereditary antithrombin III deficiency, has been reported.)17

Plasma levels of AT-III are lower in neonates than adults, averaging approximately 60% in normal term infants.18,19 AT-III levels in premature infants may be much lower.18,19 Low plasma AT-III levels, especially in a premature infant, therefore, do not necessarily indicate hereditary deficiency. It is recommended that testing and treatment with Antithrombin III (Human), THROMBATE III® of neonates be discussed with an expert on coagulation.11


See all Thrombate III indications & dosage >>

THROMBATE III NEWS HIGHLIGHTS

Published Studies Related to Thrombate III (Antithrombin III)

Antithrombin III for critically ill patients. [2008.07.16]

Antithrombin for respiratory distress syndrome in preterm infants. [2006.10.18]

Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. [2006.05]

High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. [2006.02]

Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. [2006.01]

more >>

Clinical Trials Related to Thrombate III (Antithrombin III)

Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery [Completed]

Study to Assess Recombinant Human Antithrombin in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery [Completed]

Safety, Pharmacokinetics and Efficacy of an AT-III Concentrate. [Recruiting]

Recombinant Human Antithrombin (ATrynŽ) in the Treatment of Patients With DIC Associated With Severe Sepsis [Recruiting]

Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement [Recruiting]

more >>

Page last updated: 2008-08-10

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008